Ever Supreme Bio Technology Statistics

Total Valuation

Ever Supreme Bio Technology has a market cap or net worth of TWD 13.96 billion. The enterprise value is 13.32 billion.

Market Cap	13.96B
Enterprise Value	13.32B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Ever Supreme Bio Technology has 80.67 million shares outstanding. The number of shares has decreased by -1.91% in one year.

Current Share Class	n/a
Shares Outstanding	80.67M
Shares Change (YoY)	-1.91%
Shares Change (QoQ)	-0.30%
Owned by Insiders (%)	3.49%
Owned by Institutions (%)	3.48%
Float	57.90M

Valuation Ratios

The trailing PE ratio is 55.00.

PE Ratio	55.00
Forward PE	n/a
PS Ratio	16.55
PB Ratio	8.82
P/TBV Ratio	8.88
P/FCF Ratio	33.91
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 32.58, with an EV/FCF ratio of 32.37.

EV / Earnings	52.39
EV / Sales	15.77
EV / EBITDA	32.58
EV / EBIT	35.18
EV / FCF	32.37

Financial Position

The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.00.

Current Ratio	3.31
Quick Ratio	2.90
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	2,669.23

Financial Efficiency

Return on equity (ROE) is 15.29% and return on invested capital (ROIC) is 14.18%.

Return on Equity (ROE)	15.29%
Return on Assets (ROA)	12.40%
Return on Capital (ROIC)	14.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.44
Inventory Turnover	2.75

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.00% in the last 52 weeks. The beta is 0.28, so Ever Supreme Bio Technology's price volatility has been lower than the market average.

Beta (5Y)	0.28
52-Week Price Change	-2.00%
50-Day Moving Average	178.53
200-Day Moving Average	186.45
Relative Strength Index (RSI)	39.16
Average Volume (20 Days)	168,103

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ever Supreme Bio Technology had revenue of TWD 844.86 million and earned 254.33 million in profits. Earnings per share was 3.15.

Revenue	844.86M
Gross Profit	591.48M
Operating Income	379.03M
Pretax Income	334.82M
Net Income	254.33M
EBITDA	397.66M
EBIT	379.03M
Earnings Per Share (EPS)	3.15

Full Income Statement

Balance Sheet

The company has 638.43 million in cash and 5.70 million in debt, giving a net cash position of 632.74 million or 7.84 per share.

Cash & Cash Equivalents	638.43M
Total Debt	5.70M
Net Cash	632.74M
Net Cash Per Share	7.84
Equity (Book Value)	1.58B
Book Value Per Share	19.61
Working Capital	635.97M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 416.91 million and capital expenditures -5.31 million, giving a free cash flow of 411.60 million.

Operating Cash Flow	416.91M
Capital Expenditures	-5.31M
Free Cash Flow	411.60M
FCF Per Share	5.10

Full Cash Flow Statement

Margins

Gross margin is 70.01%, with operating and profit margins of 44.86% and 30.10%.

Gross Margin	70.01%
Operating Margin	44.86%
Pretax Margin	39.63%
Profit Margin	30.10%
EBITDA Margin	47.07%
EBIT Margin	44.86%
FCF Margin	48.72%

Dividends & Yields

This stock pays an annual dividend of 5.45, which amounts to a dividend yield of 3.15%.

Dividend Per Share	5.45
Dividend Yield	3.15%
Dividend Growth (YoY)	231.16%
Years of Dividend Growth	n/a
Payout Ratio	173.02%
Buyback Yield	1.91%
Shareholder Yield	5.06%
Earnings Yield	1.82%
FCF Yield	2.95%

Dividend Details

Stock Splits

The last stock split was on May 29, 2024. It was a forward split with a ratio of 1.1000011.

Last Split Date	May 29, 2024
Split Type	Forward
Split Ratio	1.1000011

Scores

Ever Supreme Bio Technology has an Altman Z-Score of 31.78.

Altman Z-Score	31.78
Piotroski F-Score	n/a